Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definition
1.2 Base estimates & workings
1.2.1 Data collection
1.3 Forecast calculations
1.4 Data Sources
1.4.1 Primary
1.4.2 Secondary
1.4.2.1 Paid sources
1.4.2.2 Unpaid sources
Chapter 2 Executive Summary
2.1 Global point of care testing market 360° synopsis, 2018 – 2032 (Revenue)
2.2 Business trends
2.3 Regional trends
2.4 Product trends
2.5 Technology trends
2.6 Prescription trends
2.7 Application trends
2.8 End-use trends
Chapter 3 Point of Care Testing Industry Insights
3.1 COVID- 19 impact analysis
3.2 Industry ecosystem analysis
3.3 Technology landscape
3.4 Pricing analysis, by cardiac markers, 2022
3.5 Regulatory landscape
3.6 Industry impact forces
3.6.1 Growth drivers
3.6.1.1 Upward trend in disease prevalence among developing countries
3.6.1.2 Surging number of pathology labs and services equipped with advanced diagnostic equipment in North America
3.6.1.3 Technological advancements
3.6.1.4 Increasing R&D investment
3.6.2 Industry pitfalls & challenges
3.6.2.1 Stringent regulatory framework
3.6.2.2 High cost of product development
3.7 Growth potential analysis
3.7.1 By product
3.7.2 By technology
3.7.3 By prescription
3.7.4 By application
3.7.5 By end-use
3.8 Porter's analysis
3.9 PESTEL analysis
Chapter 4 Competitive Landscape, 2022
4.1 Introduction
4.2 Company market share analysis, 2022 (by region)
4.2.1 Global market share analysis, 2022
4.2.2 North America
4.2.3 Europe
4.2.4 Asia Pacific
4.2.5 Latin America
4.2.6 MEA
4.3 Competitive analysis of major market players, 2022
4.4 Company positioning matrix, 2022
4.5 Strategy outlook matrix, 2022
Chapter 5 Point of Care Testing Market Estimates and Forecast, By Product (Revenue)
5.1 Key trends, by product
5.2 Glucose monitoring
5.2.1 Strips
5.2.2 Meters
5.2.3 Lancets
5.3 Cardiometabolic testing products
5.3.1 Cardiac marker testing products
5.3.1.1 hsTnl
5.3.1.2 BNP
5.3.1.3 D-dimer
5.3.1.4 CK-MB
5.3.1.5 Myoglobin
5.3.1.6 Others
5.3.2 Blood gas/electrolytes testing products
5.3.3 HBA1C testing products
5.4 Infectious disease testing products
5.4.1 Influenza testing products
5.4.2 HIV testing products
5.4.3 Hepatitis C testing products
5.4.4 Sexually transmitted disease (STD) testing products
5.4.5 Healthcare-associated infection (HAI) testing products
5.4.6 Respiratory infection testing products
5.4.7 Tropical disease testing products
5.4.8 Others
5.5 Coagulation testing products
5.5.1 PT/INR testing products
5.5.2 Activated clotting time (ACT/APTT) testing products
5.6 Pregnancy and fertility testing products
5.6.1 Pregnancy testing products
5.6.2 Fertility testing products
5.7 Tumor/cancer marker testing products
5.8 Cholesterol testing products
5.9 Hematology testing products
5.10 Drug-of-abuse (DoA) testing products
5.11 Fecal occult testing products
5.12 Urinalysis testing products
5.13 Others
Chapter 6 Point of Care Testing Market Estimates and Forecast, By Technology (Revenue)
6.1 Key trends, by technology
6.2 Lateral flow assays
6.3 Dipsticks
6.4 Microfluidics
6.5 Molecular diagnostics
6.6 Immunoassays
6.7 Agglutination assays
6.8 Flow-through
6.9 Solid phase
6.10 Biosensors
Chapter 7 Point of Care Testing Market Estimates and Forecast, By Prescription (Revenue)
7.1 Key trends, by prescription
7.2 OTC testing
7.3 Prescription-based testing
Chapter 8 Point of Care Testing Market Estimates and Forecast, By Application (Revenue)
8.1 Key trends, by application
8.2 Cardio metabolic testing
8.3 Infectious disease testing
8.4 Nephrology testing
8.5 Drug-of-abuse (DoA) testing
8.6 Blood glucose testing
8.7 Pregnancy testing
8.8 Cancer biomarker testing
8.9 Others
Chapter 9 Point of Care Testing Market Estimates and Forecast, By End-use (Revenue)
9.1 Key trends, by end-use
9.2 Hospitals
9.3 Diagnostic centers
9.4 Research laboratories
9.5 Home-care settings
9.6 Others
Chapter 10 Point of Care Testing Market Estimates and Forecast, By Region (Revenue)
10.1 Key trends, by region
10.2 North America
10.2.1 U.S.
10.2.2 Canada
10.3 Europe
10.3.1 Germany
10.3.2 UK
10.3.3 France
10.3.4 Italy
10.3.5 Spain
10.3.6 Switzerland
10.3.7 The Netherlands
10.3.8 Denmark
10.3.9 Poland
10.3.10 Sweden
10.4 Asia Pacific
10.4.1 China
10.4.2 Japan
10.4.3 India
10.4.4 Australia
10.4.5 South Korea
10.4.6 New Zealand
10.4.7 Thailand
10.4.8 Vietnam
10.4.9 Indonesia
10.5 Latin America
10.5.1 Brazil
10.5.2 Mexico
10.5.3 Argentina
10.5.4 Colombia
10.5.5 Chile
10.6 Middle East & Africa
10.6.1 Saudi Arabia
10.6.2 South Africa
10.6.3 UAE
10.6.4 Turkey
Chapter 11 Company Profiles
11.1 Abaxis
11.2 Abbott Laboratories
11.3 ACON Laboratories, Inc
11.4 Accubiotech Co, Ltd.
11.5 Becton, Dickinson and Company
11.6 bioLytical Laboratories Inc
11.7 BioMerieux SA
11.8 Bio-Rad Laboratories, Inc
11.9 HemoCue AB (Danaher Corporation)
11.10 Dexcom, Inc
11.11 Dragerwerk Ag & Co
11.12 LifeScan IP Holdings, LLC
11.13 Medtronic Plc
11.14 Meridian Bioscience
11.15 Nova Biomedical
11.16 OraSure Technologies
11.17 F. Hoffmann-La Roche
11.18 Siemens Healthineers AG
11.19 Sysmex Corporation
11.20 Trinity Biotech
